Circulating tumor cells in breast cancer

Current Opinion in Obstetrics and Gynecology

Volumn 20, Issue 1, 2008, Pages 55-60

  Ignatiadis, Michail ^a,b   Georgoulias, Vassilis ^a,b   Mavroudis, Dimitris ^a,b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Breast cancer; Cytokeratin 19 mRNA; Phenotyping; Prediction; Prognosis; Reverse transcription PCR

Indexed keywords

CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; TAMOXIFEN;

BONE MARROW CELL; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CIRCULATING TUMOR CELL; DNA FINGERPRINTING; GENE EXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TUMOR CELL;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOMAGNETIC SEPARATION; KERATIN-19; NEOPLASM CIRCULATING CELLS; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 38149037275     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3282f22b2e     Document Type: Review

References (43)

1. Asworth TR. A case of cancer in which cells similar to those in tumors were seen in the blood after death. Aust Med J 1869; 14:146-149.
2. Slade MJ, Coombes RC. The clinical significance of disseminated tumor cells in breast cancer. Nat Clin Pract Oncol 2007; 4:30-41. This paper provides an excellent review in the field of CTCs.
3. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 2006; 13:1033-1067. This paper provides an excellent review in the field of CTCs.
4. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007; 253:180-204. This paper provides an excellent review in the field of CTCs.
5. Pusztai L, Cristofanilli M, Paik S. New generation of molecular prognostic and predictive tests for breast cancer. Semin Oncol 2007; 34:S10-S16. This paper provides an excellent review in the field of CTCs.
6. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12:6403-6409. This study suggests that CTCs detected by CellSearch is a superior surrogate endpoint than standard radiology tests for predicting overall survival in metastatic breast cancer.
7. Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12:4218-4224.
8. Cristofanilli M, Broglio KR, Guarneri V, et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer 2007; 7:471-479.
9. Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007; 13:920-928.
10. Mueller V, Riethdorf S, Loibl S, et al. Prospective monitoring of circulating tumor cells in breast cancer patients treated with primary systemic therapy - a translational project of the German Breast Group study GeparQuattro. Proc Am Soc Clin Oncol 2007; 25:abstract 21085.
11. Smerage JB, Hayes DF, Doyle GV, et al. Assessment of circulating tumor cells in breast cancer patients undergoing neoadjuvant chemotherapy. Proc Am Soc Clin Oncol 2006; 24:abstract 10079.
12. Rack B, Schindlbeck C, Hofmann S, et al. Circulating tumor cells (CTCs) in peripheral blood of primary breast cancer patients. Proc Am Soc Clin Oncol 2007; 25:abstract 10595.
13. Stathopoulou A, Ntoulia M, Perraki M, et al. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int J Cancer 2006; 119:1654-1659.
14. Ntoulia M, Stathopoulou A, Ignatiadis M, et al. Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin Biochem 2006; 39:879-887.
15. Silva HA, Abraul E, Raimundo D, et al. Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients. Eur J Cancer 2006; 42:2617-2622.
16. Gargano G, Agnese V, Calo V, et al. Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. Ann Oncol 2006; 17 (suppl. 7):vii41-vii45.
17. Mercatali L, Valenti V, Calistri D, et al. RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. Ann Oncol 2006; 17:424-428.
18. Iakovlev VV, Goswami RS, Vecchiarelli J, et al. Quantitative detection of circulating epithelial cells by Q-RT-PCR. Breast Cancer Res Treat 2007 [epub ahead of print].
19. Zehentner BK, Secrist H, Hayes DC, et al. Detection of circulating tumor cells in peripheral blood of breast cancer patients during or after therapy using a multigene real-time RT-PCR assay. Mol Diagn Ther 2006; 10:41-47.
20. Ferrucci PF, Rabascio C, Gigli F, et al. A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer. Int J Oncol 2007; 30:955-962.
21. Xenidis N, Perraki M, Kafousi M, et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 2006; 24:3756-3762. This was the first study to show that the detection of CK-19 mRNA-positive CTCs is an independent prognostic factor for worse outcome in node-negative early breast.
22. Ignatiadis M, Xenidis N, Perraki M, et al. Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early breast cancer. J Clin Oncol 2007, in press.
23. Alix-Panabieres C, Vendrell JP, Pelle O, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007; 53:537-539. This study describes the development of a technique for the detection of protein secreting cells.
24. Apostolaki S, Perraki M, Pallis A, et al. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 2007; 18:851-858. This study shows that the molecular detection of HER2 mRNA-positive cells after the administration of adjuvant chemotherapy is an independent prognostic factor for short disease-free interval in early breast cancer.
25. Ignatiadis M, Perraki M, Apostolaki S, et al. Molecular detection and prognostic value of circulating CK-19 mRNA- and HER2 mRNA-positive cells in the peripheral blood of women with early breast cancer. Clin Breast Cancer 2007, in press.
26. Yie SM, Luo B, Ye NY, et al. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA. Clin Exp Metastasis 2006; 23:279-289.
27. Xenidis N, Markos V, Apostolaki S, et al. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann Oncol 2007; 18:1623-1631. This study shows that the detection of CK-19 mRNA-positive CTCs during tamoxifen administration predicts worse outcome in early breast cancer.
28. Benoy IH, Elst H, Philips M, et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 2006; 94:672-680.
29. Kowalewska M, Chechlinska M, Markowicz S, et al. The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes. Eur J Cancer 2006; 42:2671-2674.
30. Ignatiadis M, Desmedt C. Predicting risk of breast cancer recurrence using gene-expression profiling. Pharmacogenomics 2007; 8:101-111.
31. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007; 7:545-553.
32. Teschendorff AE, Miremadi A, Pinder SE, et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007; 8:R157.
33. Wong NS, Kahn HJ, Zhang L, et al. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treat 2006; 99:63-69.
34. Wulfing P, Borchard J, Buerger H, et al. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 2006; 12:1715-1720. This study demonstrates that the immunocytochemical detection of HER2-positive CTCs predicts poor outcome in early breast cancer.
35. Kallergi G, Mavroudis D, Georgoulias V, Stournaras C. Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 2007; 13:79-88. This study is an excellent example of individual CTC phenotyping.
36. Meng S, Tripathy D, Shete S, et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 2006; 103:17361-17365. This study is an excellent example of individual CTC phenotyping.
37. Reuben JM, Lee BN, Broglio KR, et al. Genomic of circulating tumor cells in metastatic breast cancer. Proc Am Soc Clin Oncol 2007; 25:abstract 1002.
38. Amin A, Stojadinovic A, Holmes JP, et al. Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with a preventive HER2/neu E75-peptide vaccine. Proc Am Soc Clin Oncol 2007; 25:abstract 3059.
39. Magbanua M, Lang JE, Scott JH et al. Isolation and molecular profiling of circulating tumor cells (CTCs) from breast cancer patients. Breast Cancer Res Treat 2006; 100 (suppl 1):abstract 5002.
40. Hartmann CH, Klein CA. Gene expression profiling of single cells on large-scale oligonucleotide arrays. Nucleic Acids Res 2006; 34:e143. This study provides evidence that gene-expression profiling of single cells using oligonucleotide arrays is feasible.
41. Cristofanilli M, Mendelsohn J. Circulating tumor cells in breast cancer: advanced tools for 'tailored' therapy? Proc Natl Acad Sci U S A 2006; 103:17073-17074.
42. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005; 23:9067-9072.
43. Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 2006; 11:541-552. This article outlines key issues for tumor marker evaluation in diagnosis, monitoring and treatment of breast cancer.